Trials / Completed
CompletedNCT04767581
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Comparative Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Kyowa Kirin Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between hemodialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and those receiving placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KHK7791 | oral administration |
| DRUG | Placebo | oral administration |
Timeline
- Start date
- 2021-03-08
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
- First posted
- 2021-02-23
- Last updated
- 2021-09-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04767581. Inclusion in this directory is not an endorsement.